News | March 06, 2024
Bayer strengthens pharma portfolio with new cardiology drug acoramidis
Acquisition of exclusive commercialization rights for European markets
Acquisition of exclusive commercialization rights for European markets
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Almost 300 million people globally have chronic hepatitis B
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Subscribe To Our Newsletter & Stay Updated
